Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market Close
Rhea-AI Summary
Tevogen (Nasdaq: TVGN) entered a $3 million PIPE financing with existing investor The Patel Family, LLP. The deal comprises 375,000 prefunded warrants at $8.00 each, a 14% premium to the May 11, 2026 close, and is expected to close around May 13, 2026.
Proceeds will support operations, strategic growth, and general corporate purposes. The unregistered securities will be covered by a planned SEC resale registration statement.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- PIPE raises $3 million in gross proceeds
- Pricing at $8.00 per prefunded warrant, a 14% premium to last close
- Support from existing investor The Patel Family, LLP is reaffirmed
- Company plans SEC registration statement for resale of warrant shares
Negative
- Issuance of 375,000 prefunded warrants implies future dilution for common shareholders
- Securities are initially unregistered and subject to resale restrictions
News Market Reaction – TVGN
On the day this news was published, TVGN declined 0.43%, reflecting a mild negative market reaction. Argus tracked a peak move of +16.3% during that session. Argus tracked a trough of -14.2% from its starting point during tracking. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $157K from the company's valuation, bringing the market cap to $36.39M at that time. Trading volume was very high at 3.3x the daily average, suggesting heavy selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 27 | AI platform update | Positive | -7.3% | PredicTcell™ training nearing completion with ~10% precision improvement. |
| Mar 26 | CRO acquisition talks | Positive | -8.1% | Advanced evaluation of CRO deal targeting $20M+ added annual revenue. |
| Mar 25 | Nasdaq compliance | Positive | -0.8% | Regained Nasdaq minimum bid-price compliance after reverse stock split. |
| Mar 18 | Conference appearance | Positive | +3.1% | Tevogen.AI leadership presenting AI work at Microsoft Fabric conference. |
| Mar 13 | Capital discipline update | Positive | -15.7% | Reaffirmed limited share use, tight float, and potential revenue-adding deals. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive corporate updates have frequently been followed by negative next-day price reactions.
Over the last six months, Tevogen has focused on technology, clinical infrastructure, and capital structure. An AI update on PredicTcell™ and a strategic CRO evaluation aimed at adding $20M+ annual revenue both saw negative next-day moves. The company regained Nasdaq bid-price compliance via a 1-for-50 reverse split and highlighted capital discipline, including limiting share utilization to 1% of authorized shares, yet those announcements also coincided with declines. Against this backdrop, the new $3M PIPE at an $8.00 premium price adds to a series of capital-focused steps.
Regulatory & Risk Context
Key Terms
private investment in public equity financial
pipe financial
prefunded warrants financial
registration statement regulatory
u.s. securities and exchange commission regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
WARREN, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that it has entered into a securities purchase agreement for a private investment in public equity (the “PIPE”) financing with existing investor The Patel Family, LLP for gross proceeds of
Pursuant to the terms of the securities purchase agreement, Tevogen will issue 375,000 prefunded warrants each exercisable for the purchase of one share of the Company’s common stock. The PIPE financing was priced at
“Having The Patel Family, LLP continue to support Tevogen reflects a shared belief in both our mission and our long-term vision for building a more accessible and sustainable healthcare model,” said Tevogen Bio founding CEO Ryan Saadi, MD, MPH. “We believe this financing along with an existing ATM offering and loan agreement, provides the company with access to adequate capital to reach revenue milestones."
“Our continued investment emphasizes our conviction in Tevogen, its leadership and novel technology, and we look forward to being long-term holders,” said investor Dr. Manmohan Patel, MD, on behalf of The Patel Family, LLP.
The securities issued in the PIPE financing have not been registered under the Securities Act of 1933, as amended, or applicable state securities laws. Accordingly, the securities may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. In connection with the private placement, the Company has agreed to file a registration statement with the U.S. Securities and Exchange Commission covering the resale of the shares issuable upon exercise of the prefunded warrants.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
About Tevogen
Tevogen is a socially integrated healthcare enterprise built on the principles of affordability, efficiency, and scientific rigor. The company leverages artificial intelligence and precision T cell therapy platforms, a patient-first and cost-disciplined operating model, and engagements with global technology leaders to support the development of advanced, life-saving therapies across multiple therapeutic areas and scalable solutions for the broader healthcare system.
Tevogen Bio, the company’s lead initiative, has completed a proof-of-concept clinical trial demonstrating the potential of its single-HLA-restricted, genetically unmodified allogeneic T cells. Tevogen Bio’s pipeline spans virology, oncology, and neurology, with programs built on the company’s proprietary ExacTcell™ platform.
Tevogen.AI is designed to transform drug development by accelerating target detection, helping reduce failure rates, and supporting optimized clinical trial design through proprietary predictive technologies. The platform utilizes cloud and data services from leading technology providers, including Microsoft and Databricks, to advance its long-term ambition to predict the proteome for any given protein–HLA combination, enabling rapid and cost-efficient therapeutic discovery.
Tevogen is exploring future strategic initiatives that may include domestic generics, biosimilars, medical devices, and innovative insurance solutions for healthcare providers. Together, these programs reflect Tevogen’s mission to advance sustainable innovation and broaden patient access through a faster, more efficient, and more equitable healthcare model.
Forward Looking Statements
This press release contains certain forward-looking statements, including without limitation statements relating to: expectation regarding the benefits of the financing; strategic initiatives and the potential benefits of the initiatives; Tevogen’s plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.
Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: the risk that the financing transaction may not close; risks inherent in execution of strategic initiatives; the risk that the expected benefits of the initiatives may not be realized on a timely basis or at all; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; that Tevogen will need to raise additional capital to fully realize its business plans; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s most recent Annual Report on Form 10-K and subsequent filings with the SEC.
You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.
Contact
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
